Αρχειοθήκη ιστολογίου

Πέμπτη 13 Οκτωβρίου 2022

Association of Neoadjuvant Pembrolizumab for OCSCC With Adverse Events After Surgery

alexandrossfakianakis shared this article with you from Inoreader

ooi220048t1_1664995493.14313.png?Expires

This cohort study evaluates the incidence of postoperativ e adverse events in treatment-naive patients receiving neoadjuvant pembrolizumab for advanced oral cavity cancer when compared with matched controls.
View on Web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου